微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 33.94% | 3.25% | 4.89% | 102/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 32.36% | -2.56% | -3.46% | 111/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 33.52% | 2.98% | -1.12% | 107/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 33.9% | 3.67% | 3.12% | 108/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 32.87% | 2.64% | -1.02% | 106/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 33.21% | 2.5% | 2.03% | 113/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 32.55% | 2.17% | -0.46% | 112/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 32.7% | 3.06% | 2.09% | 113/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 32.03% | -2.54% | -1.15% | 112/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 32.4% | 1.56% | 1.7% | 113/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 31.86% | 0.27% | 0.41% | 113/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 31.73% | -3.03% | -3.45% | 117/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 32.86% | -2.73% | 3.01% | 112/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 31.9% | 3.97% | 0.41% | 117/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 31.77% | 1.61% | -2.9% | 109/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 32.72% | 0.56% | -3.14% | 112/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 33.78% | -2.78% | 10.09% | 102/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 30.69% | -7.16% | -1.87% | 123/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 31.27% | -8.98% | -3.9% | 108/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 32.54% | -9.34% | -6.36% | 116/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 34.75% | -14.08% | 5.14% | 96/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 33.05% | 3.14% | -3.8% | 122/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 34.36% | 6.23% | -4.28% | 101/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 35.89% | 7.63% | -11.25% | 105/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 40.44% | 16.05% | 26.2% | 80/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 32.05% | 10.55% | -0.91% | 114/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 32.34% | 9.57% | -3.02% | 90/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 33.35% | 9.68% | -4.31% | 94/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 34.85% | 10.09% | 20.22% | 84/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 28.99% | 10.97% | -1.78% | 117/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 29.51% | 12.81% | -2.92% | 88/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 30.4% | 14.17% | -3.95% | 90/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 31.65% | 12.43% | 21.18% | 82/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 26.12% | 7.61% | -0.16% | 110/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 26.16% | 3.7% | -1.75% | 85/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 26.63% | 0.81% | -5.42% | 86/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 28.15% | -0.39% | 15.99% | 66/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 24.27% | 1.24% | -3.79% | 99/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 25.23% | 3.62% | -4.48% | 69/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 26.41% | 4.9% | -6.55% | 75/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 28.27% | 4.1% | 17.89% | 60/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |